Clinical trials: Tislelizumab
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Hodgkin Lymphoma
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
The goal of this clinical trial is to test the effect of tislelizumab treatment in patients with Hodgkin lymphoma. The main question it aims to answer is whether including a drug called tislelizumab in first-line treatment of…
- Trial name
- RATiFY (NCT05627115)
- Testing
- Tislelizumab, AVD, Radiotherapy
- Volunteers
- 80 people
- Sponsor
- University College, London
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
ESCC
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
This is a prospective, single-arm, exploratory, single-center clinical study designed to evaluate the efficacy and safety of becotatug vedotin (MRG003) in combination with an investigator's choice of immune checkpoint inhibitor…
- Trial name
- VISTA-ESCC (NCT07892833)
- Testing
- Becotatug vedotin (MRG003)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Immunotherapy Gastroesophageal Junction
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
- Trial name
- NCT06396585
- Testing
- Tislelizumab, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
Lung Adenocarcinoma
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug…
- Trial name
- NCT06056115
- Testing
- Tislelizumab,Platinum
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Medical University Fourth Hospital
Muscle Invasive Bladder Cancer
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
This trial is designed to evaluate the safety, efficacy, and biomarker response of APL-1202 in combination with tislelizumab as neoadjuvant therapy for patients with MIBC who are cisplatin ineligible or refuse cisplatin-based…
- Trial name
- ANTICIPATE (NCT04813107)
- Testing
- APL-1202 in combination with tislelizumab, Tislelizumab alone
- Where
- 2 sites in United States, China
- Volunteers
- 79 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Long-Term Effects Secondary to Cancer Therapy
Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC
A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC…
- Trial name
- NCT06356701
- Testing
- Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Peripheral T Cell Lymphoma, PTCL
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell…
- Conditions
- Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type
- Trial name
- NCT03493451
- Testing
- Tislelizumab
- Where
- 24 sites in Canada, China and 3 more
- Volunteers
- 77 people
- Sponsor
- BeiGene
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University
Adenocarcinoma, Stomach Neoplasm
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of radiotherapy combined with chemotherapy and anti-PD-1 immunotherapy followed by surgery for the primary and metastatic lesions in patients with limited…
- Conditions
- Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
- Trial name
- Miracle-G (NCT06121700)
- Testing
- Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
- Conditions
- Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma, Digestive System Neoplasms
- Trial name
- NCT06794073
- Testing
- Multimodal Thermal Therapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-Small Cell Lung Cancer
Gut Microbiota Reconstruction for NSCLC Immunotherapy
In this study, patients with locally advanced or metastatic NSCLC after first-line treatment with PD-1/PDL-1 monoclonal antibody will be treated with Gut Microbiota reconstruction(such as FMT) combined with PD-1/PDL-1 monoclonal…
- Trial name
- NCT05008861
- Testing
- Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Platinum based chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT06951841
- Testing
- Liposome Irinotecan, Platinum, Tislelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
This is a prospective, non-interventional, observational study evaluating the efficacy and immune microenvironment changes in Patients with Advanced Hepatocellular Carcinoma treated with TACE Combined with PD-1 Inhibitor.
- Trial name
- TASK-01-RW (NCT07100405)
- Testing
- PD-1 inhibitor, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume < 700ml or estimated liver-GTV V5 < 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis…
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Tislelizumab, Tumor Thrombosis
- Trial name
- NCT06233981
- Testing
- Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
This is a multicenter, open-label, single-arm phase II study evaluating the efficacy and safety of mannatide in combination with CAPOX chemotherapy and tislelizumab as first-line treatment for patients with recurrent or…
- Trial name
- NCT07655661
- Testing
- Oxaliplatin, Capecitabine, Tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Ming Liu